+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of Adjuvant Chemotherapy on Oncologic Outcomes following Radical Nephroureterectomy for Patients with pT3NanyM0 Upper Tract Urothelial Carcinoma: A retrospective cohort study



Impact of Adjuvant Chemotherapy on Oncologic Outcomes following Radical Nephroureterectomy for Patients with pT3NanyM0 Upper Tract Urothelial Carcinoma: A retrospective cohort study



International Journal of Surgery 2019



We investigated the impact of cisplatin-based adjuvant chemotherapy (AC) on oncologic outcomes including recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS) after radical nephroureterectomy (RNU) for patients with pT3NanyM0 upper tract urothelial carcinoma (UTUC). We retrospectively reviewed 293 patients who underwent RNU for UTUC between 1995 and 2017. Clinicopathologic characteristics of patients were examined and compared according to the use of AC. Kaplan-Meier survival analysis was used to illustrate RFS, CSS and OS. Cox proportional hazard models were applied to identify factors predicting oncologic outcomes. Among the 293 total patients, 127 (43.3%) patients received AC. During a mean follow-up of 59.7 months, recurrence and/or distant metastasis were identified in 124 (42.3%) patients, and 106 (36.2%) patients died overall, of which 93 (31.7%) died from UTUC. The 5-year RFS, CSS and OS rates of overall patients were 51.3%, 68.0% and 64.7%, respectively. In multivariate analysis, AC was inversely associated with tumor recurrence (HR =0.74, P = 0.028) but not significantly associated with death from UTUC (P = 0.237) and death from all-cause (P = 0.433). The 5-year RFS of patients who had received AC was 58.0%, while 44.0% for patients who had only been observed after RNU. AC improved RFS, but did not have a significant effect on CSS and OS in patients with pT3NanyM0 UTUCs following RNU. Further efforts are needed to identify reliable criteria in the clinic for patients that would benefit from AC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066720693

Download citation: RISBibTeXText

PMID: 31018160

DOI: 10.1016/j.ijsu.2019.04.013


Related references

Impact of adjuvant chemotherapy in patients with pT3NanyM0 upper tract urothelial cancer following radical nephroureterectomy. European Urology Suppl.s 16(3): E305-E306, 2017

Oncologic outcomes of high-risk upper tract urothelial carcinoma patients undergoing radical nephroureterectomy combined with adjuvant chemotherapy. Zhonghua Yi Xue Za Zhi 99(2): 115-119, 2019

Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. European Urology 63(6): 1134-1135, 2013

Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy. Korean Journal of Urology 56(1): 41-47, 2015

Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. European Urology 63(6): 1082-1090, 2013

Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. Journal of Urology 191(2): 316-322, 2014

Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Oncotargets and Therapy 10: 5775-5782, 2017

Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. European Urology 65(1): 210-217, 2014

Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. Bju International 121(2): 252-259, 2017

Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma. International Journal of Clinical Oncology 23(4): 726-733, 2018

The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. Bju International 116(1): 72-78, 2015

The Influence of Tumor Size on Oncologic Outcomes for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy. Biomed Research International 2016: 4368943, 2017

Prognostic Impact of Preoperative Albumin-Globulin Ratio on Oncologic Outcomes in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. Clinical Genitourinary Cancer 16(5): E1059-E1068, 2018

Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology 36(4): 645-653, 2018

Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. Urology 94: 148-153, 2017